New cancer drug trial hopes to reawaken immune cells against tumors

NCT ID NCT05083481

Terminated Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a safe dose, then to test that dose in more people, either alone or with other cancer treatments like pembrolizumab (Keytruda) or chemotherapy. However, the trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP1570 (an experimental oral drug that aims to reactivate T-cells against tumors)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This trial was terminated early, so results are limited. It is an early-phase study (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China
California Research Institute

Los Angeles, California, 90027, United States
Cancer Institute Hospital Of JFCR

Koto-ku, Tokyo, Japan
ES34008

Málaga, Spain
FR33005

Saint-Herblain, France
FR33007

Besançon, France
FR33008

Paris, France
FR33009

Toulouse, France
Florida Cancer Specialist & Research Institute Sarasota

Sarasota, Florida, 34232, United States
Mary Crowley Research Center

Dallas, Texas, 75230, United States
National Cancer Center Hospital

Chuo-ku, Tokyo, Japan
Nebraska Methodist Hospital

Omaha, Nebraska, 68130, United States
Providence Medical Foundation

Fullerton, California, 92835, United States
Puerto Rico Medical Center

Río Piedras, Puerto Rico
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)

Hangzhou, Zhejiang, China
Shanghai East Hospital

Shanghai, China
Site ES34002

Madrid, Spain
Site ES34005

A Coruña, Barcelona, Spain
Site ES34006

Pozuelo de Alarcón, Spain
Site ES34007

Málaga, Spain
Site FR33002

Bordeaux, France
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Kentucky Medical Center MCC-CRO

Lexington, Kentucky, 40536, United States
University of Wisconsin Clinical Science Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.